(0.33%) 5 116.76 points
(0.33%) 38 365 points
(0.36%) 15 986 points
(-0.92%) $83.08
(5.56%) $2.03
(0.35%) $2 355.30
(0.41%) $27.65
(3.97%) $958.75
(-0.24%) $0.932
(-0.39%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 11.62%
Live Chart Being Loaded With Signals
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox...
Stats | |
---|---|
本日の出来高 | 54 973.00 |
平均出来高 | 431 248 |
時価総額 | 81.34M |
EPS | $0 ( 2024-02-29 ) |
次の収益日 | ( $-0.210 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.980 |
ATR14 | $0.00500 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Kozin Marc D | Buy | 100 000 | Stock Option (Right to Buy) |
2024-03-20 | Kozin Marc D | Buy | 0 | |
2024-02-14 | Andriole Michael T. | Sell | 1 744 | Common Stock |
2024-02-14 | Laspaluto Michelle | Sell | 1 940 | Common Stock |
2024-02-14 | Jakeman David | Sell | 2 660 | Common Stock |
INSIDER POWER |
---|
88.94 |
Last 99 transactions |
Buy: 5 160 750 | Sell: 1 392 397 |
ボリューム 相関
Chimerix Inc 相関
10 最も負の相関 | |
---|---|
PTOC | -0.971 |
MCFT | -0.969 |
LGAC | -0.964 |
APXI | -0.963 |
NVSA | -0.962 |
AGGR | -0.961 |
GFGD | -0.961 |
FRSG | -0.959 |
FTPA | -0.959 |
ACQR | -0.959 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Chimerix Inc 相関 - 通貨/商品
Chimerix Inc 財務諸表
Annual | 2023 |
収益: | $324 000 |
総利益: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2023 |
収益: | $324 000 |
総利益: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2022 |
収益: | $33.82M |
総利益: | $33.38M (98.68 %) |
EPS: | $1.970 |
FY | 2021 |
収益: | $1.98M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.01 |
Financial Reports:
No articles found.
Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。